Athira Pharma Inc Ordinary Shares ATHA
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if ATHA is a good fit for your portfolio.
News
-
Athira Pharma Appoints Javier San Martin, M.D., as Chief Medical Officer
-
Athira Pharma Announces Publication of Preclinical Data Highlighting Fosgonimeton Treatment in Models of Alzheimer’s Disease
-
Athira Pharma Announces Upcoming Poster Presentation at American Academy of Neurology (AAN) 2024 Annual Meeting
-
Athira Pharma Presents Clinical and Preclinical Data Supporting Therapeutic Potential of Fosgonimeton in Alzheimer’s and Parkinson’s Diseases at AD/PD™ 2024 International Conference
-
Athira Pharma Reports Full Year 2023 Financial Results and Pipeline and Business Updates
-
Athena Gold Completes IP/Resistivity Survey at its Crow Springs Copper-Molybdenum-Gold Porphyry Project in Nevada
-
Athira Pharma Announces Publication in Frontiers in Neuroscience Highlighting Therapeutic Potential of ATH-1105 in Amyotrophic Lateral Sclerosis (ALS)
Trading Information
- Previous Close Price
- $2.01
- Day Range
- $1.90–2.00
- 52-Week Range
- $1.33–4.30
- Bid/Ask
- $1.92 / $2.18
- Market Cap
- $73.59 Mil
- Volume/Avg
- 156,023 / 366,782
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Athira Pharma Inc is a late clinical-stage biopharmaceutical company focused on developing small molecules engineered to restore neuronal health and slow neurodegeneration. Its pipeline candidates are; Fosgonimeton (ATH-1017) a subcutaneously administered, small molecule positive modulator of the HGF/MET system for CNS disorders, ATH-1020 is a novel small molecule compound designed to be an orally available once-daily treatment, to enhance the HGF/MET system. ATH-1105 is a novel small molecule compound designed to be an orally available once-daily treatment, to enhance the HGF/MET system, and several other compounds in preclinical discovery and development for neurodegenerative diseases, including ATH-1018 and ATH-1019.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 67
- Website
- https://www.athira.com
Comparables
Valuation
|
Metric
|
ATHA
|
SAVA
|
RPHM
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 0.56 | 6.37 | 0.63 |
Price/Sales | — | — | — |
Price/Cash Flow | — | — | — |
Price/Earnings
ATHA
SAVA
RPHM
Financial Strength
|
Metric
|
ATHA
|
SAVA
|
RPHM
|
|---|---|---|---|
Quick Ratio | 5.17 | 8.60 | 5.66 |
Current Ratio | 5.37 | 9.13 | 5.87 |
Interest Coverage | — | — | — |
Quick Ratio
ATHA
SAVA
RPHM
Profitability
|
Metric
|
ATHA
|
SAVA
|
RPHM
|
|---|---|---|---|
Return on Assets (Normalized) | −52.05% | −47.53% | −60.40% |
Return on Equity (Normalized) | −59.31% | −51.26% | −68.46% |
Return on Invested Capital (Normalized) | −58.75% | −55.59% | −67.67% |
Return on Assets
ATHA
SAVA
RPHM
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Ggnvcffgd | Pvkj | $562.4 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Swljgws | Qtytmk | $103.6 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Mwndkyfbb | Pxjzl | $99.5 Bil | |
MRNA
| Moderna Inc | Qhjzwgqp | Nxtk | $38.8 Bil | |
ARGX
| argenx SE ADR | Kdlhprp | Chhhh | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Tncnzwzr | Dhgm | $21.2 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Jpcyzbj | Gdvshg | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Tthdjbxtj | Csjlztt | $17.3 Bil | |
RPRX
| Royalty Pharma PLC Class A | Jtjywzmxt | Lcqwsj | $12.5 Bil | |
INCY
| Incyte Corp | Vfflgcw | Pbvmwr | $11.6 Bil |